Moderna, Inc. MRNA Chief Executive

What Stéphane Bancel says in public, and what their own SEC filings show they own.

Stéphane Bancel

Stéphane Bancel

Chief Executive Officer & Director · Moderna, Inc.

CEO since 2011 and the company's largest individual shareholder; signed the Q2 2026 10-Q as principal executive officer.

What they own

Ownership

Skin in the game
31/ 70
Level 2Aligned

Bancel owns about 3% of Moderna, Inc., worth $2.50B at the last close.

SEC filings
341
Stake 13.0M reported shares ≈ 3.3% of shares outstanding — no 13G on file, so an estimate 20/35
Founder Not assessed — whether they founded the company has not been researched Not assessed
Tenure No start date on record, so tenure scores nothing 0/10
Track record Not assessed — their prior companies have not been researched Not assessed
Direction Exercise-and-sell — 499,246 shares ($28.7M) sold, all covered by option exercises; the underlying stake is flat 4/15
Discipline 2 late Form 4s in 341 filings 7/10

Nobody has researched this person's career yet, so founder and track record are left out of the score and of the total above.

Score = stake band (35) + founder (15) + tenure (10) + track record (15) + 12-month direction (−10…15) + filing discipline (10). An axis we have not researched is left out of the score and of the total it is shown over. Every input links to a filing or to our own research; the bands are ours.

Reported · Forms 3, 4, 5 13.0M Every lot on the person's own filings, as of Aug 6, 2026
Last open-market trade Sale · $28.7M Aug 5, 2026 · 499,246 shares at $57.52 avg · under a 10b5-1 plan
Paper trail 2 late filings Form 4 covering a 2020-07-01 gift in Moderna, Inc. was filed 2020-07-08, 4 business days later; Section 16 allows two.
Reported Moderna, Inc. shares Forms 3, 4 and 5 · as of 2026-08-06
05M10M15M20M 20192020202120222023202420252026 Aug 2026: net +252,469 shares across 3 movements (largest: exercise +499,246)Feb 2026: net +5,821 shares across 2 movements (largest: award +11,271)Dec 2025: net +688,073 shares across 1 movement (largest: exercise +688,073) 13.0M

Dots mark the months the activity below moved the line. Hover one for that month's net move, how many movements it folds and the largest.

How the stake is held
SecurityHeld viaShares
Common StockSee Footnote6,564,880
Common StockDirect6,440,260
Reported as of 2026-08-0613,005,140
Held directly
50%
Vehicles
1 trust or entity
Last filing
Aug 7, 2026
Activity · last 12 months 6 events folded from 9 filing lines · Every filing on EDGAR ↗
DateTypeWhat happenedSharesPriceValueNote
Aug 6, 2026 Exercise Option or RSU conversion +252,469 $19.15 $4.8M
Aug 5, 2026 Exercise Option or RSU conversion +499,246 $19.15 $9.6M
Aug 5, 2026 Sale Open-market sale across 4 lots, $56.21–$58.79 −499,246 $57.52 avg $28.7M under a 10b5-1 plan
Feb 11, 2026 Award Grant or award +11,271 — —
Feb 11, 2026 Tax Shares withheld for tax −5,450 $41.99 $229K
Dec 11, 2025 Exercise Option or RSU conversion +688,073 $10.90 $7.5M
Every issuer Stéphane Bancel files as an insider of
CompanyRoleReportedBeneficial% of class
MRNA Moderna, Inc. This page Chief Executive Officer 13M
2026-08-06		 — —
GENB Generate Biomedicines, Inc. Director 1,184,989
2026-03-02		 — —
BGMD BG Medicine, Inc. Director 123,167
2012-11-15		 — —
SYRS Syros Pharmaceuticals, Inc. Director 47,980
2016-07-06		 — —

Reported is every lot on the person's own Forms 3, 4 and 5 — direct and through trusts. Beneficial is the figure stated on the latest Schedule 13D/G cover page, which can exclude shares the person disclaims and include options exercisable within 60 days, so the two are never added together.

Paper trail

341 filings under CIK 0001443340 · captured 2026-09-05 · All filings on EDGAR ↗

On the record with shareholders

Earnings calls

  1. Q2 2026 Jul 31, 2026 Bancel's argument was that a seasonally empty quarter is the wrong place to look for the story. Revenue of $145 million was above the top of the guided range but is what a respiratory vaccine business earns in a June quarter; what he asked investors to hold on to instead was cash cost down 10% year on year, a full-year cash-cost target cut to roughly $4 billion, a year-end cash balance guided $0.2 billion higher, and up to 10% revenue growth still intact for 2026 — a burn being managed down while the pipeline decides the company's value. The growth he pointed to is not in this quarter's line: the EU's pandemic-era exclusive supply arrangement expires in 2026 and opens Europe to Moderna for the first time, a fifth product was days from a US decision at the 5 August flu PDUFA date, and the Phase 3 melanoma interim for intismeran was expected in the second half. The norovirus interim, which missed its early-success criteria, he treated as a case-accrual delay rather than a verdict. Read the call · 3 quotes →
In their own words

Podcasts, interviews & articles

5 recorded appearances

2026

Interview CNBC Squawk Box · Aug 19, 2026 · 16 min

Watch CNBC's full interview with Moderna CEO Stephane Bancel & Merck Research Laboratories President Dr. Dean Li

Bancel and Merck's Dean Li presented the first positive late-stage results for their individualised mRNA cancer vaccine, and argued the shot combined with Keytruda could become a new melanoma treatment option.

Watch or read →

Who else runs a company like this one

Every CEO we track →
David A. Ricks David A. Ricks Eli Lilly and Company (LLY) Joaquin Duato Joaquin Duato Johnson & Johnson (JNJ) Robert A. Michael AbbVie Inc. (ABBV) Stephen J. Hemsley Stephen J. Hemsley UnitedHealth Group Incorporated (UNH) Andrew Dudum Hims & Hers Health, Inc. (HIMS)